Seaport Therapeutics Inc. Common Stock (SPTX)
Stock · NASDAQ · Health Care
$17.83as of 10/16/2026
Price chart
Active signals
No technical signal is currently active for this symbol.
Support level
$17.79
Industry
Biotechnology: Pharmaceutical Preparations
About SPTX
Seaport Therapeutics, Inc., a clinical-stage therapeutics company, focuses on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. It is leveraging its proprietary Glyph platform to advance a pipeline of therapies to address the unmet needs in depression and anxiety. The company's lead product candidate, GlyphAllo (SPT-300 or Glyph Allopregna…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 58
- Website
- seaporttx.com
Fundamentals
- 1-day range
- $17.14$17.98
- Market cap
- $1.24B
- P/E (trailing)
- —
- P/E (forward)
- -6.98
- EPS (trailing)
- $-1.65
- Dividend yield
- —
- Beta
- 0.61
- Avg. volume
- 187.5K
52-week range
$14.85$28.38
Next earnings: November 12, 2026 · EPS estimate $-0.56
Forecasts
8 analyst ratings
Buy 85%
Hold 15%
Sell 0%
1-year price forecast
High
$50
+180.4%
Median
$35
+96.3%
Low
$28
+57.0%
Seaport Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- SPTXSeaport Therapeutics Inc. Common Stock$17.83▲ 1.31%Market cap $1.24BP/E —$14.85$28.38
- MNKDMannKind Corporation Common Stock$3.04▼ 4.70%Market cap $1.24BP/E —$2.23$6.51
- ETONEton Pharmaceuticals Inc. Common Stock$50.31▼ 1.99%Market cap $1.26BP/E 133.39$14.27$66.37
- ARDXArdelyx Inc. Common Stock$3.09▼ 5.50%Market cap $1.20BP/E —$3.06$8.4
- XERSXeris Biopharma Holdings Inc. Common Stock$10.31▲ 2.38%Market cap $1.27BP/E —$5.25$11.33
- SVRASavara Inc. Common Stock$4.45▼ 6.12%Market cap $1.19BP/E —$3.38$7.01
- WVEWave Life Sciences Ltd. Ordinary Shares$3.13▼ 1.88%Market cap $1.19BP/E —$3.56$21.73
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| SPTX Seaport Therapeutics Inc. Common Stock | $1.24B | — | $17.83 | ▲ 1.31% | $14.85$28.38 |
| MNKD MannKind Corporation Common Stock | $1.24B | — | $3.04 | ▼ 4.70% | $2.23$6.51 |
| ETON Eton Pharmaceuticals Inc. Common Stock | $1.26B | 133.39 | $50.31 | ▼ 1.99% | $14.27$66.37 |
| ARDX Ardelyx Inc. Common Stock | $1.20B | — | $3.09 | ▼ 5.50% | $3.06$8.4 |
| XERS Xeris Biopharma Holdings Inc. Common Stock | $1.27B | — | $10.31 | ▲ 2.38% | $5.25$11.33 |
| SVRA Savara Inc. Common Stock | $1.19B | — | $4.45 | ▼ 6.12% | $3.38$7.01 |
| WVE Wave Life Sciences Ltd. Ordinary Shares | $1.19B | — | $3.13 | ▼ 1.88% | $3.56$21.73 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- This Tower Semiconductor Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For FridayBenzinga · 9/25/2026
- Raymond James Initiates Coverage On Seaport Therapeutics with Strong Buy Rating, Announces Price Target of $46Benzinga · 9/25/2026
- PureTech Health PLC (PTCHF) (H1 2026) Earnings Call Highlights: Cash Runway to 2028, Seaport's ...Yahoo · 9/22/2026
- PureTech Health H1 Earnings Call HighlightsYahoo · 9/22/2026
- Seaport Therapeutics to Participate in September Investor ConferencesYahoo · 9/14/2026
Insider Activity
Insider Actions →Acquired
19.13M
Disposed
60.15M
- Robert J. Hombach · June 22, 2026 · Buy13.0K @ $18.14
- PureTech Health plc · May 4, 2026 · Conversion8.42M
- PureTech Health plc · May 4, 2026 · Conversion40.00M
- PureTech Health plc · May 4, 2026 · Conversion965.3K
- PureTech Health plc · May 4, 2026 · Conversion2.68M
- PureTech Health plc · May 4, 2026 · Conversion12.74M
- Gladstein Lana · May 4, 2026 · Conversion105.3K
- Loebel Antony · May 4, 2026 · Conversion20.1K
- James Healy · May 4, 2026 · Conversion2.53M
- James Healy · May 4, 2026 · Conversion6.05M
- Keith Crandell · May 4, 2026 · Conversion2.68M
- PureTech Health plc · May 4, 2026 · Conversion3.03M
- Gladstein Lana · May 4, 2026 · Conversion33.5K
- Chen Michael Cunyuan · May 4, 2026 · Conversion10.5K
- Chen Michael Cunyuan · May 4, 2026 · Conversion3.4K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Seaport Therapeutics Gains Analyst Attention Ahead of ECNP Data
Seaport Therapeutics has attracted new analyst coverage, with Canaccord Genuity and HC Wainwright both issuing price targets of $28 and $50 respectively. The company will present additional pharmacokinetic data from its Phase 1 GlyphAgo trial at the ECNP Congress in October. These developments add fresh information for investors to assess the drug’s progress. The stock remains near its 52‑week low, with a support level around $17.79.
Seaport Therapeutics Gains Analyst Attention Ahead of ECNP Data. Seaport Therapeutics has attracted new analyst coverage, with Canaccord Genuity and HC Wainwright both issuing price targets of $28 and $50 respectively. The company will present additional pharmacokinetic data from its Phase 1 GlyphAgo trial at the ECNP Congress in October. These developments add fresh information for investors to assess the drug’s progress. The stock remains near its 52‑week low, with a support level around $17.79.